Musical Chairs for BMS Pharma Research: For $24M, It s Deltagen s Turn to Run the Shop | GenomeWeb

NEW YORK, Feb. 11 - Deltagen has dipped its toes deeper into drug-development waters with its proposed acquisition of Bristol-Myers Squibb's Pharma Research Labs division.
 
The acquisition, which will cost roughly $23.5 million in stock, gives Deltagen the keys to a small molecule-drug discovery firm.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.